ArticleTranslational cancer research2023

Fruquintinib in combination with sintilimab or TAS-102 as third-line or above treatment in patients with metastatic colorectal cancer: a real-world study.

Luchun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.